CeraVe vs. Zerobase: Danby et al. (2022) Intrapatient RCT on Skin Barrier Repair

Duration

28 days (4 weeks) of twice-daily treatment, with assessments at baseline, day 15, day 28, and day 31 (following a post-treatment sodium lauryl sulfate [SLS] irritant patch challenge).

Population

Adults with dry, eczema-prone (atopic-dermatitis-predisposed) skin and abnormal stratum corneum lipid levels; 56% had currently active eczema at baseline. Predominantly White participants (31/34), with 2 Asian and 1 Mixed-ethnicity; all recruited in the UK. Findings should not be assumed to generalize across skin types/ethnicities not well represented in this sample.

Limitations

Single UK site with a predominantly White sample (31/34 participants), limiting generalizability across skin types and ethnicities. Short 4-week treatment window; durability beyond that period is unknown. Intrapatient (split-body, forearm/lower-leg) design measures within-subject relative differences under controlled application (2 fingertip units, twice daily) rather than real-world, whole-body, self-directed use. FTIR depth-profiling covered only the outer ~1.0-1.5 µm of stratum corneum (~70% of its thickness), so deeper-layer lipid changes were not directly measured. Study is industry-funded by the test product's manufacturer. Age-stratified (≥60y) subgroup differences, while numerically larger, were not statistically confirmed as significant and should be read as exploratory/hypothesis-generating only.

Sample size

36 adults enrolled; 34 completed the 4-week protocol (21 female, 13 male; mean age 43±18 years, range 20-89) per the Oxford Academic (BJD) article page. Note: the University of Sheffield's White Rose Research Online repository abstract summary states '34 adults' without separately distinguishing enrolled vs. completed - likely an abstract-level simplification rather than a true discrepancy, but both figures are given here since the two fetched sources phrase it differently.

Study design

Single-center (Sheffield, UK), randomized, observer-blind, intrapatient (split-body) controlled interventional trial. Each participant applied the test cream to one randomized forearm+lower leg and the reference cream to the contralateral sites, serving as their own control.

Outcome metric

Primary: transepidermal water loss (TEWL) area-under-curve during sequential tape stripping (barrier integrity); TEWL and visual/instrumental (chromameter) erythema response to a 24-hour SLS irritant patch test; resting TEWL. Secondary: skin capacitance (hydration), visual dryness scoring, cumulative stratum corneum protein removed by tape stripping (cohesion). Exploratory: FTIR spectroscopy-measured lipid chain/lamellar ordering and stratum corneum water-content depth profile (sampling depth ~1.0-1.5 µm, roughly the outer 70% of stratum corneum).

Funding conflicts

Funded by L'Oréal (U.K.) Limited, the manufacturer/marketer of the test product (CeraVe); the funder is stated to have reviewed but not directed study design, data collection, or analysis, per the Oxford Academic article summary. Lead/senior authors S.G. Danby and M.J. Cork disclosed consultancy/advisory relationships with multiple pharmaceutical and personal-care companies (specific company names were not captured in the fetched summaries). Co-authors P.V. Andrew, L.J. Kay, A. Pinnock, J. Chittock, K. Brown, and S.F. Williams declared no conflicts. This is a manufacturer-funded, brand-vs-competitor-brand comparison - a material conflict of interest to weigh when interpreting effect sizes favoring the funder's product.

Research question

In adults with dry, eczema-prone skin, does twice-daily use of a ceramide/cholesterol/triglyceride physiological-lipid cream (CeraVe Moisturising Cream) versus a paraffin-based reference emollient (Zerobase) without physiological lipids improve stratum corneum lipid lamellar structure and skin barrier function (transepidermal water loss, hydration, irritant sensitivity) over 4 weeks?

Does not establish

Does not establish that ceramide-containing moisturizers as a class outperform all non-ceramide emollients - only that this specific test cream outperformed this specific paraffin-based reference cream. Does not establish efficacy, safety, or barrier benefit for any other product, SKU, or brand not tested here. Does not establish long-term (beyond 4 weeks) outcomes, reduction in clinical eczema flare frequency/severity, or disease-modifying effects. Does not establish real-world effectiveness under unsupervised, whole-body, self-administered use (the trial used a controlled split-body/fingertip-unit dosing protocol). Does not establish generalizability to skin types/ethnicities underrepresented in this mostly White, UK-recruited sample of 34-36 adults. Is not a regulatory or drug-efficacy determination - this is a cosmetic-emollient comparative trial, not an FDA/EMA-reviewed therapeutic claim.

Result effect size

TEWL area-under-curve (barrier integrity): effect size −161.9, 95% CI −205.5 to −118.3, favoring test cream (lower = better barrier). SLS-induced TEWL: −15.3 g/m²/h, 95% CI −20.3 to −10.4. SLS visual erythema: −0.5 points, 97.57% CI −1.00 to −0.25. SLS objective redness (chromameter): −25.1 AU, 95% CI −38.9 to −11.4. Resting TEWL at 4 weeks: 1.21 g/m²/h lower with test cream, 95% CI 0.34-2.1. Skin capacitance (hydration) at 4 weeks: +8.61 units, 95% CI 6.61-10.6 (approx. 50% increase with test cream vs. <10% with reference). Cumulative stratum corneum protein removed: −65.9 µg/cm², 95% CI −87.4 to −44.4. FTIR lipid peak frequency shift: 0.23 cm⁻¹ lower with test cream, 95% CI 0.17-0.29 (more ordered orthorhombic lipid packing), correlated with barrier integrity (r=0.61) and hydration (r=0.72). Subgroup effect sizes were numerically larger in participants ≥60 years for most outcomes, but the age-group difference itself was not reported as statistically significant - exploratory only. 28 total adverse events reported; 8 possible adverse reactions (7 on reference-cream sites, 1 on test-cream site).

Product equivalence

Results are specific to the two exact formulations tested - CeraVe Moisturising Cream vs. Zerobase cream - under an intrapatient split-body design. The authors' own stated limitation is that findings 'cannot be generalized to other ceramide-containing products' merely because they share ingredient categories (e.g., other 'ceramide creams,' other CeraVe product-line SKUs, or other 'barrier repair' claims). No other brand, formulation, or delivery system (e.g., non-multivesicular-emulsion ceramide products) was tested, so no equivalence claim beyond these two named products is supported by this data.

Intervention control

Test product: CeraVe Moisturising Cream (L'Oréal/CeraVe) - ceramides NP, AP, EOP, plus phytosphingosine, cholesterol, glycerin, sodium hyaluronate, tocopherol and triglycerides in a multivesicular emulsion. Control product: Zerobase cream (Thornton & Ross Ltd) - a simple paraffin-based emollient without physiological lipids, described as commonly prescribed in the UK. Both applied as 2 fingertip units, twice daily, ≥6 hours apart, to randomized contralateral forearm and lower-leg sites for 28 days.

All research records · Corrections: see our corrections policy.